Merck (MRK) is seeing renewed attention from investors this week, thanks to a pivotal event in its oncology pipeline. The company, in collaboration with Daiichi Sankyo, just secured Breakthrough ...

Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s earnings beat estimates, its sales came in line. Earnings of $2.13 per ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the ...

Merck’s strong oncology gains, 4% yield, and low PEG ratio support its value case despite sector risks and patent concerns.

EXEL rides on Cabometyx momentum and pipeline gains, while MRK leans on Keytruda dominance and a diverse portfolio for growth.

After six days of gains, shares dropped, reflecting mixed momentum. See insights on earnings, cost-cutting, and analyst ratings.

Merck’s stock is falling after a rare revenue miss, and the announcement of a $3 billion cost-cutting plan that will include ...

Merck(NYSE: MRK), a leading pharmaceutical company, generates consistent revenue and profits. However, the stock has been under pressure over the past year due to its reliance on Keytruda, its ...

Merck & Co. Inc. closed 28.45% below its 52-week high of $120.30, which the company achieved on September 6th.

Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s earnings beat estimates, its sales came in line.

Merck is seeking ways to prepare for a significant upcoming patent cliff. The company has just announced another acquisition that will help it achieve that goal. With its newer products, strong ...